Who is sponsoring NCT03891472?

NCT03891472 is sponsored by Medical University of Silesia.

What condition does NCT03891472 study?

NCT03891472 studies Cancer of Pancreas, Unresectable Pancreatic Cancer, Chemotherapy Effect, SBRT.

Is NCT03891472 still recruiting?

NCT03891472 is currently completed. Last updated 13 November 2019.

Last reviewed 2019-11-13 · How we verify

NCT03891472

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer

Completed Phase 2 Last updated 13 November 2019

What this trial tests

Phase 2 trial testing Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy. in Cancer of Pancreas in 40 participants. Completed in 31 July 2019.

Timeline

1 January 2017

Primary endpoint
31 July 2019

31 July 2019

Quick facts

Lead sponsor	Medical University of Silesia
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 January 2017
Primary completion	31 July 2019
Estimated completion	31 July 2019
Sites	1 location across Poland

Drugs / interventions tested

Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.

Conditions studied

Cancer of Pancreas — all drugs for Cancer of Pancreas →
Unresectable Pancreatic Cancer — all drugs for Unresectable Pancreatic Cancer →
Chemotherapy Effect — all drugs for Chemotherapy Effect →
SBRT — all drugs for SBRT →

Sponsor

Medical University of Silesia

Who can join

18 and older, any sex, with Cancer of Pancreas or Unresectable Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary goal: Improvement of the therapeutic index by reducing the toxicity of treatment and increasing local control of the cancer process while evaluating the possibility of conversion to the surgical status. Secondary targets: * Survival rate (OS) assessment in patients treated with mFOLFIRINOX + SBRT * Assessment of quality of life using questionnaires: EQ-5D, EORTC (QLQ-C30) and pancreatic cancer-specific QLQ PAS module 26 * Early toxicity \<3 months after completion of SBRT treatment. * Percentage of local control (1-year)

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Photodynamic Therapy and Hyperthermia in Combination Treatment-Neglected Forces in the Fight against Cancer.
Bienia A, Wiecheć-Cudak O, Murzyn AA, Krzykawska-Serda M. · · 2021 · cited 36× · PMID 34452108 · DOI 10.3390/pharmaceutics13081147
Combination of modified FOLFIRINOX with stereotactic body radiotherapy as an induction therapy for locally advanced pancreatic adenocarcinoma - a prospective single-arm study.
Piątek M, Bieńkowski M, Kuśnierz K, Pilch-Kowalczyk J, et al · · 2024 · cited 2× · PMID 38800534 · DOI 10.5114/wo.2024.137760

Verify or expand the search:

Other recruiting trials for Cancer of Pancreas

Currently open trials in the same condition.

NCT06940778 — LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TU · active not recruiting
NCT05485974 — A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation · Phase 1 · active not recruiting
NCT06344507 — Iconographic Registry of Pancreatobiliary Endoscopy Procedures · recruiting
NCT05163028 — A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations · Phase 1 · active not recruiting
NCT04677244 — Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level · NA · recruiting

Other Medical University of Silesia trials

Trials by the same sponsor.

NCT06212674 — Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients · Phase 4 · recruiting
NCT06970002 — Respiratory Stabilization in Chronic Acidosis Before Bronchofiberoscopy & Non-Invasive Ventilation Effectivenes · NA · not yet recruiting
NCT07137299 — POPQ Associated With Total Laparoscopic Hysterectomy · not yet recruiting
NCT06970041 — To Assess the Types of Mechanical Ventilation in Enabling Therapeutic Bronchofiberoscopy in Patients With Decompensated · NA · not yet recruiting
NCT07120529 — Minimally Invasive Surgery Versus Open Radical Hysterectomy in Presumably Early Stage Cervical Cancer: a Retrospective M · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03891472 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Silesia
Last refreshed: 13 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03891472.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing